Reply: RE: Reyes A, Revil C, Niggli M, et al. Efficacy of emicizumab prophylaxis versus factor VIII prophylaxis for treatment of hemophilia A without inhibitors: network meta-analysis and sub-group analyses of the intra-patient comparison of the HAVEN 3 trial. Curr Med Res Opin. 2019;35(12):2079-2087.

Adriana Reyes,Cedric Revil,Markus Niggli,Sammy Chebon,Simone Schlagmüller,J.-P. Flacke,Max Zortel,Ido Paz-Priel,Elina Asikanius,Roger Hampton,Anadi Mahajan,Elvira Schmidt,Susan C. Edwards

Reply: RE: Reyes A, Revil C, Niggli M, et al. Efficacy of emicizumab prophylaxis versus factor VIII prophylaxis for treatment of hemophilia A without inhibitors: network meta-analysis and sub-group analyses of the intra-patient comparison of the HAVEN 3 trial. Curr Med Res Opin. 2019;35(12):2079-2087.

2020

Adriana Reyes
Cedric Revil
Markus Niggli
Sammy Chebon
Simone Schlagmüller
J.-P. Flacke
Max Zortel
Ido Paz-Priel
Elina Asikanius
Roger Hampton
Anadi Mahajan
Elvira Schmidt
Susan C. Edwards

Dear Editor,We thank Jain and Lethagen for the opportunity to clarify some points of interest.As outlined in Mahlangu et al.1, emicizumab prophylaxis has demonstrated a statistically significant an...

Keywords:

Diabetes mellitus
Anesthesia
Medicine
relative efficacy
Emicizumab
Meta-analysis
Internal medicine

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations